Clinical trials: Human Immunodeficiency Virus Infection
Hepatitis B, Chronic, Hepatocellular Carcinoma
PROLIFICA - West African Treatment Cohort for Hepatitis B
The West African Treatment Cohort for Hepatitis B (WATCH) study is a component of the European Commission Funded FP7 project PROLIFICA.
- Trial name
- WATCH (NCT02129829)
- Testing
- Tenofovir disoproxil
- Where
- 2 sites in Senegal, The Gambia
- Volunteers
- 1,079 people
- Sponsor
- Imperial College London
Cervical Cancer, Human Papilloma Virus
HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV
Our study will assess and measure population effectiveness of prophylactic HPV vaccine in reducing cervical, anal, and/or oral prevalent and 6-month persistent infections among HPV-vaccinated and 757 HPV-unvaccinated Rwandan WLWH…
- Conditions
- Cervical Cancer, Human Papilloma Virus, Human Immunodeficiency Virus, HPV-Related Carcinoma
- Trial name
- NCT05247853
- Testing
- Blood collection, Oral, cervicovaginal and anal specimen collection, Anoscopy & Biopsy of Acetowhite Lesions
- Where
- Rwanda
- Volunteers
- 3,127 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Lung Cancer, Lymphoma
Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
RATIONALE: Collecting and studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01567722
- Testing
- DNA analysis, RNA analysis, gene expression analysis
- Where
- 14 sites in United States
- Volunteers
- 114 people
- Sponsor
- AIDS Malignancy Consortium
Healthy Subjects, Hepatic Impairment
GSK1349572 Hepatic Impairment Study
GSK1349572 is an integrase inhibitor that is currently in clinical development for the treatment of human immunodeficiency virus (HIV) infection.
- Conditions
- Healthy Subjects, Hepatic Impairment, Infection, Human Immunodeficiency Virus, HIV Infections
- Trial name
- NCT01231529
- Testing
- GSK1349572
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Hepatitis C, Medication Adherence
Intensive Models of HCV Care for Injection Drug Users
Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). HCV treatment leading to sustained viral response (SVR) is associated with increased survival.
- Trial name
- NCT01857245
- Testing
- Intensive Models (mDOT and CGT) of HCV Care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Prisma Health-Upstate
Mycobacterium Avium-Intracellulare Infection, HIV Infections
A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo
To compare the efficacy of clarithromycin/ethambutol with placebo or with rifabutin at two different doses in reducing colony-forming units (CFUs) by 2 or more logarithms in patients with Mycobacterium avium Complex bacteremia…
- Trial name
- NCT00002101
- Testing
- Ethambutol hydrochloride, Clarithromycin, Rifabutin
- Where
- 44 sites in United States
- Volunteers
- 450 people
- Sponsor
- Pharmacia
HIV Infections
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules
To evaluate the safety and immune response to vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) using an accelerated dosage schedule; to evaluate duration of antibody response and its relationship to the dose and…
- Trial name
- NCT00000957
- Testing
- gp160 Vaccine (Immuno-AG)
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Osteopenia
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
Given the high prevalence of bone alteration in the course of HIV infection or antiretroviral treatment and the favourable properties of raltegravir the investigators designed this pilot randomized and controlled study.
- Trial name
- RALBAT (NCT01902186)
- Testing
- raltegravir and atazanavir and ritonavir, tenofovir/emtricitabine and atazanavir and ritonavir
- Where
- 2 sites in Italy
- Volunteers
- 4 people
- Sponsor
- Giovanni Di Perri
HIV Infections
A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection
To determine the safety and maximum tolerated dose (MTD) of 2',3'-dideoxyinosine (ddI), given orally and intravenously, in infants and children with AIDS.
- Trial name
- NCT00000669
- Testing
- Didanosine
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Hepatitis C
Safety Study of Raltegravir in HIV/HCV Co-infected Patients
Current European AIDS Clinical Society (EACS) guidelines for the treatment of HIV infection recommend a combination antiretroviral regimen composed of two nucleoside reverse transcriptase inhibitors plus a ritonavir boosted…
- Trial name
- NCT01225705
- Testing
- raltegravir, Atazanavir/ritonavir
- Where
- 8 sites in Germany
- Sponsor
- University Hospital, Bonn
HIV-1 Infection, HIV Reservoir
Intestinal Tissue-Resident Memory T Cells and HIV-1 Persistence During Antiretroviral Therapy
The study aims to better characterize intestinal tissue-resident memory T cells (TRM) in people living with HIV-1 receiving suppressive antiretroviral therapy (ART).
- Conditions
- HIV-1 Infection, HIV Reservoir, Antiretroviral Therapy
- Trial name
- ANRSGALT-2 (NCT07656077)
- Testing
- Colonic Mucosal Biopsies
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
Background: Human papilloma virus (HPV) is a common sexually transmitted disease. There are more than 100 different HPV types, and both males and females can get HPV infection.
- Conditions
- Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
- Trial name
- NCT00798265
- Testing
- Gardasil, Survey
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infection
Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment
A selection study in treatment naive HIV patients to compare the virologic success rate of once daily antiretroviral treatment regimens at the 48th week with Epzicom(lamivudine and abacavir) plus efavirenz and Epzicom plus…
- Trial name
- NCT00280969
- Testing
- atazanavir arm, efavirenz
- Where
- Japan
- Volunteers
- 71 people
- Sponsor
- International Medical Center of Japan
HIV/AIDS, Cancer
IMPACt of an Enhanced Screening Program on the Detection of Non-AIDS NEOplasms in HIV Patients
Introduction: The incidence of malignancies is higher in the HIV-infected population than in the general population, and it is already one of the leading causes of death in people living with the virus.
- Trial name
- IMPACNEO (NCT04735445)
- Testing
- Digital rectal exam and / or anal cytology (day 1 and after 36 months), Semestral digital rectal exam and / or anal cytology if abnormal → ANOSCOPY with biopsy, Cervical cytology and cervical sample for HPV detection (day 1 and after 36 months)
- Where
- Spain
- Volunteers
- 4,638 people
- Sponsor
- Felix Gutierrez
HIV Infections, HPV Infection
Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)
This study aims to conduct a randomized controlled trial to evaluate the effectiveness of same-day HPV-based screen and treat among women living with HIV (WLH) in La Romana, Dominican Republic.
- Conditions
- HIV Infections, HPV Infection, Cervical Cancer
- Trial name
- (iSTAR) (NCT07225530)
- Testing
- Screen, Triage, and Treat
- Where
- Dominican Republic
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Columbia University
HIV Infection, HIV
#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.
The #aware.hiv Europe study is a real-world, multicenter, stepped-wedge cluster randomized, effectiveness-implementation trial designed to evaluate whether the introduction of dedicated HIV teams in hospitals can improve HIV…
- Conditions
- HIV Infection, HIV, Stigma, Education
- Trial name
- #aware hiv (NCT06900829)
- Testing
- HIV team implementation
- Where
- 28 sites in Belgium, France and 8 more
- Volunteers
- 5,200 people, healthy volunteers welcome
- Sponsor
- Casper Rokx
HIV (Human Immunodeficiency Virus), HPV
Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Screen Positive Women Living With HIV in C1001P-CS2 Kenya
Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general…
- Conditions
- HIV (Human Immunodeficiency Virus), HPV, Cervical Precancer
- Trial name
- NCT07468695
- Testing
- Thermal ablation (TA) with 1 probe, Thermal ablation (TA) with 2 probes
- Where
- Kenya
- Volunteers
- 300 people
- Sponsor
- Fred Hutchinson Cancer Center
HIV Infections
Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults
Primary purpose of this study is to compare the efficacy and safety of two different nevirapine (Viramune) dosing regimens (once daily (QD) and twice daily (BID) application) and of atazanavir/ritonavir (Reyataz/Norvir), all on…
- Trial name
- NCT00389207
- Testing
- nevirapine bid, nevirapine qd, atazanavir
- Where
- 68 sites in Argentina, Germany and 8 more
- Volunteers
- 576 people
- Sponsor
- Boehringer Ingelheim
HIV - Human Immunodeficiency Virus, Obesity
DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity
Background:Historically, HIV infection was associated with significant weight loss. However, weight gain is now commonly observed after initiating antiretroviral therapy (ART), particularly in individuals underweight at baseline.
- Conditions
- HIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity
- Trial name
- COATL (NCT07075146)
- Testing
- DOR/3TC/TDF, BIC/FTC/TAF
- Where
- Mexico
- Volunteers
- 306 people
- Sponsor
- José Antonio Mata Marín
Infections, Streptococcal
Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
The purposes of this study: To evaluate the immunogenicity, safety and reactogenicity of pneumococcal vaccine GSK1024850A in HIV infected infants, HIV exposed uninfected infants and HIV unexposed uninfected infants following a…
- Trial name
- NCT00829010
- Testing
- Pneumococcal vaccine GSK1024850A, Tritanrix-HepB/Hib, measles
- Where
- South Africa
- Volunteers
- 489 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline